FDA Approved: NUPLAZID — Supplemental Application (Acadia Pharmaceuticals Inc.)

View source ↗

Summary

FDA is reviewing a supplemental application for Nuplazid (pimavanserin tartrate) from Acadia Pharmaceuticals, seeking labeling changes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease Psychosis

Drugs mentioned

• Nuplazid (Pimavanserin)

Snippet

SUPPL AP for NUPLAZID (PIMAVANSERIN TARTRATE)